Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jun 10, 2026, 10:03 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: HIV Infected Individuals Clear all
Withdrawn Phase 2 Interventional

Effect of HAART Vs. Statin Treatment on Endothelial Function and Inflammation/Coagulation

NCT01515813
View directory record Official record
Conditions
HIV-1 Infection
Interventions
Pravastatin sodium, Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate
Drug
Lead sponsor
Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
Network
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
9
States / cities
Los Angeles, California • Torrance, California • St Louis, Missouri + 6 more
Source: ClinicalTrials.gov public record
Updated Jan 31, 2016 · Synced Jun 10, 2026, 10:03 AM EDT
Completed Phase 3 Interventional

The Safety and Effectiveness of Adefovir Dipivoxil in the Treatment of HIV-Infected Patients

NCT00001082
View directory record Official record
Conditions
Cytomegalovirus Infections, HIV Infections
Interventions
Levocarnitine, Adefovir dipivoxil, Adefovir dipivoxil placebo
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
13 Years and older
Enrollment
505 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1996 – 1999
U.S. locations
15
States / cities
San Francisco, California • Denver, Colorado • Washington D.C., District of Columbia + 11 more
Source: ClinicalTrials.gov public record
Updated Sep 30, 2013 · Synced Jun 10, 2026, 10:03 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Studies of HIV-1 Infection in Newly Infected Individuals in Southern Africa

NCT00006298
View directory record Official record
Conditions
HIV Infections, HIV Seronegativity
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 45 Years
Enrollment
125 participants
Healthy volunteers
Accepts healthy volunteers
U.S. locations
1
States / cities
Research Triangle Park, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 24, 2008 · Synced Jun 10, 2026, 10:03 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Therapeutic Vaccination Followed by Treatment Interruption in HIV Infected Patients

NCT00058734
View directory record Official record
Conditions
HIV Infections
Interventions
Dendritic Cells Pulsed with HIV antigens
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 60 Years
Enrollment
5 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2000
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 26, 2007 · Synced Jun 10, 2026, 10:03 AM EDT
Active, not recruiting Phase 1 Interventional

Evaluate the Safety, Immunologic, and Virologic Responses of Donor Derived (DD) HIV-Specific T-cells (HST) in HIV-infected Individuals Following Allogeneic Bone Marrow Transplantation (alloRESIST)

NCT04248192
View directory record Official record
Conditions
HIV-Infected Individuals
Interventions
DD HST-NEETs
Biological
Lead sponsor
Catherine Bollard
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 28, 2025 · Synced Jun 10, 2026, 10:03 AM EDT
Withdrawn Not applicable Interventional

Effect of a Change in HIV Therapy on Liver Steatosis, Inflammation, and Fibrosis

NCT00023218
View directory record Official record
Conditions
HIV Infections, Hepatitis C
Interventions
Lopinavir/Ritonavir, Efavirenz
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
13 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
3
States / cities
Honolulu, Hawaii • Tripler AMC, Hawaii • New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 8, 2015 · Synced Jun 10, 2026, 10:03 AM EDT
Completed No phase listed Observational

Neurocognitive Effects and Tolerability of Efavirenz in Aging HIV-infected Individuals ("SHAC Neuro Study")

NCT01985399
View directory record Official record
Conditions
HIV, AIDS
Interventions
Neuropsychological testing
Behavioral
Lead sponsor
Stanford University
Other
Eligibility
50 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Oct 16, 2016 · Synced Jun 10, 2026, 10:03 AM EDT
Terminated Phase 2 Interventional Results available

Vitamin E for NASH Treatment in HIV Infected Individuals

NCT03669133
View directory record Official record
Conditions
NAFLD, NASH - Nonalcoholic Steatohepatitis, HIV Infections
Interventions
Vitamin E, Placebo
Drug
Lead sponsor
Indiana University
Other
Eligibility
18 Years to 75 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
2
States / cities
Indianapolis, Indiana • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 24, 2023 · Synced Jun 10, 2026, 10:03 AM EDT
Completed Phase 1 Interventional Results available

Study to Evaluate Safety and Toxicity of Polyphenon E (EGCG) in HIV-1-Infected Individuals

NCT01433289
View directory record Official record
Conditions
HIV Infection
Interventions
Polyphenon E, Placebo
Drug
Lead sponsor
Baylor College of Medicine
Other
Eligibility
18 Years to 65 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
2
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 18, 2023 · Synced Jun 10, 2026, 10:03 AM EDT
Completed Phase 1 Interventional

A Phase I/II Trial of Vaccine Therapy of HIV-1 Infected Individuals With 50-500 CD4 Cells/mm3

NCT00000755
View directory record Official record
Conditions
HIV Infections
Interventions
rgp120/HIV-1MN, Zidovudine
Biological · Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
13 Years and older
Enrollment
168 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 1993
U.S. locations
10
States / cities
Los Angeles, California • Palo Alto, California • San Francisco, California + 4 more
Source: ClinicalTrials.gov public record
Updated Nov 3, 2021 · Synced Jun 10, 2026, 10:03 AM EDT
Terminated Phase 4 Interventional Results available

Raltegravir vs. Lopinavir/Ritonavir, Both in Combination With Truvada, in HIV+ Treatment Naive Individuals

NCT00632970
View directory record Official record
Conditions
HIV Infections
Interventions
Raltegravir, Lopinavir/Ritonavir, Truvada
Drug
Lead sponsor
George Washington University
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Aug 28, 2018 · Synced Jun 10, 2026, 10:03 AM EDT
Not listed Phase 2 Interventional

Safety and Effectiveness of Giving CPI-1189 to HIV-Infected Patients With AIDS Dementia

NCT00002414
View directory record Official record
Conditions
HIV Infections
Interventions
CPI-1189
Drug
Lead sponsor
Centaur Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
6
States / cities
San Diego, California • Chicago, Illinois • Baltimore, Maryland + 3 more
Source: ClinicalTrials.gov public record
Updated Jun 23, 2005 · Synced Jun 10, 2026, 10:03 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

First-in-human Study of 10-1074-LS Alone and in Combination With 3BNC117-LS

NCT03554408
View directory record Official record
Conditions
Human Immunodeficiency Virus
Interventions
10-1074-LS, 3BNC117-LS
Drug
Lead sponsor
Rockefeller University
Other
Eligibility
18 Years to 65 Years
Enrollment
77 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2021
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 3, 2021 · Synced Jun 10, 2026, 10:03 AM EDT
Completed No phase listed Observational

A Study of HIV and Cytomegalovirus (CMV) in HIV-Infected Patients

NCT00001089
View directory record Official record
Conditions
Cytomegalovirus Infections, HIV Infections
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
13 Years and older
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
36
States / cities
Birmingham, Alabama • Los Angeles, California • San Francisco, California + 23 more
Source: ClinicalTrials.gov public record
Updated Jun 23, 2005 · Synced Jun 10, 2026, 10:03 AM EDT
Completed Phase 1 Interventional

A Phase I Comparative Blinded Trial of Several HIV-1 Derived Immunogens in Infected Individuals With >= 500 CD4 Cells/mm3

NCT00000779
View directory record Official record
Conditions
HIV Infections
Interventions
Aluminum hydroxide, MF59, rgp120/HIV-1IIIB, rgp120/HIV-1MN, rgp120/HIV-1 SF-2, Env 2-3
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
13 Years and older
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 1996
U.S. locations
10
States / cities
Los Angeles, California • Palo Alto, California • San Jose, California + 5 more
Source: ClinicalTrials.gov public record
Updated Nov 3, 2021 · Synced Jun 10, 2026, 10:03 AM EDT
Completed Phase 2 Interventional Results available

Chloroquine for Reducing Immune Activation in HIV- Infected Individuals

NCT00819390
View directory record Official record
Conditions
HIV Infections
Interventions
Chloroquine, Placebo
Drug
Lead sponsor
Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
Network
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
15
States / cities
Birmingham, Alabama • San Diego, California • Aurora, Colorado + 11 more
Source: ClinicalTrials.gov public record
Updated Oct 12, 2014 · Synced Jun 10, 2026, 10:03 AM EDT
Completed Phase 4 Interventional Results available

BATAR: Individuals Currently Taking Boosted Atazanavir as Part of an HIV Treatment Regimen Will be Evaluated to See if Substituting Raltegravir for Nucleoside Transcriptase Inhibitors Will be Safe and Well Tolerated.

NCT00931801
View directory record Official record
Conditions
HIV
Interventions
atazanavir/raltegravir, atazanavir/tenofovir/emtricitabine
Drug
Lead sponsor
Community Research Initiative of New England
Other
Eligibility
18 Years and older
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
9
States / cities
Phoenix, Arizona • Los Angeles, California • Denver, Colorado + 6 more
Source: ClinicalTrials.gov public record
Updated Jul 20, 2017 · Synced Jun 10, 2026, 10:03 AM EDT
Completed Phase 4 Interventional Results available

H1N1 Influenza Vaccine Immunogenicity in HIV-1 Infected Patients

NCT01111162
View directory record Official record
Conditions
HIV Infections
Interventions
H1N1 vaccination
Biological
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 11, 2016 · Synced Jun 10, 2026, 10:03 AM EDT
Completed Not applicable Interventional

A Randomized Trial of the Efficacy and Safety of a Strategy of Starting With Nelfinavir Versus Ritonavir Added to Background Antiretroviral (AR) Nucleoside Therapy in HIV-Infected Individuals With CD4+ Cell Counts Less Than or Equal to 200/mm3

NCT00000859
View directory record Official record
Conditions
HIV Infections
Interventions
Indinavir sulfate, Ritonavir, Nelfinavir mesylate
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
13 Years and older
Enrollment
1,300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2001
U.S. locations
32
States / cities
San Francisco, California • Denver, Colorado • Washington D.C., District of Columbia + 13 more
Source: ClinicalTrials.gov public record
Updated Oct 28, 2021 · Synced Jun 10, 2026, 10:03 AM EDT
Completed Not applicable Interventional

The Effects of Anti-HIV Drugs in HIV-Infected Patients Who Do Not Have AIDS

NCT00001024
View directory record Official record
Conditions
HIV Infections
Interventions
Zidovudine, Didanosine
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2002
U.S. locations
8
States / cities
Palo Alto, California • San Francisco, California • Chicago, Illinois + 4 more
Source: ClinicalTrials.gov public record
Updated Oct 31, 2021 · Synced Jun 10, 2026, 10:03 AM EDT
Completed Phase 1 Interventional

Phase I Study of HIV 1 Antigen Expanded Specific T Cell Therapy

NCT02208167
View directory record Official record
Conditions
HIV
Interventions
HXTC infusion
Biological
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 65 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Oct 6, 2019 · Synced Jun 10, 2026, 10:03 AM EDT
Completed Phase 1 Interventional

Active Immunization of Asymptomatic, HIV-Infected Individuals With Recombinant GP160 HIV-1 Antigen: A Phase I/II Study of Immunogenicity and Toxicity

NCT00000977
View directory record Official record
Conditions
HIV Infections
Interventions
gp160 Vaccine (MicroGeneSys)
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 1993
U.S. locations
2
States / cities
Palo Alto, California • New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 3, 2021 · Synced Jun 10, 2026, 10:03 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Immune Response to Influenza Vaccine in HIV-Infected Individuals

NCT00069914
View directory record Official record
Conditions
HIV Infections
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
Not listed
Enrollment
165 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003 – 2005
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 3, 2008 · Synced Jun 10, 2026, 10:03 AM EDT
Completed Phase 1 Interventional

Ferumoxytol-enhanced Brain MRI in HIV-associated Neurocognitive Disorders

NCT01665846
View directory record Official record
Conditions
HIV Dementia
Interventions
Ferumoxytol
Drug
Lead sponsor
University of Hawaii
Other
Eligibility
19 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Honolulu, Hawaii
Source: ClinicalTrials.gov public record
Updated May 31, 2018 · Synced Jun 10, 2026, 10:03 AM EDT